Tag Archives | ADC antibody-drug conjugates

Biotech Rally Underway After Hitting 52 Week Low Today…Update-After Close

Can the Reversal Hold? IBB Rockets up 2.75% to 285.49 after hitting 52 week low today at 268.52. XBI up 4.22% to $55.09. Notable movers: Large caps: ABBV, ALXN, AMGN, REGN; BIIB down 0.19%, GILD lagging up only 0.72%. Mid-caps all green: ALKS,CLVS,SGEN,VRTX. All Rayno Small caps recover: CRIS,GERN,GLYC etc. ————- Green Screen Across the […]

Continue Reading 0

Can Large Cap Biopharmaceutical Stocks Outperform in 2016?

 Large Cap Biopharmaceutical Stock Valuations After Correction We previously summarized the Rayno Mid and Small Cap Portfolios for 2015, a good year despite the correction. With this post we summarized selected Sales and Earnings metrics (Source finviz.com) of important large cap biotech stocks for the purpose of analysis after the J.P. Morgan Healthcare Conference and […]

Continue Reading 0

2015 Life Science Sector Review As Biopharma Rally Fades

Biopharma Rally On Hold This is not a good week for trading. Portfolio managers are re-jiggering positions so you may not see the trends correctly. Today there was much more red than green.Many biotech stocks started rallying off the bottom in October then again around December 11. There are many cross currents in the market […]

Continue Reading 0

Biotech Rally Gains Momentum…Update-1

Update-1 Rayno Recap for week of 11/20/15 IBB up 3.04%, XBI  up 1.92%,  XLV up 2.82% Notable Small Cap Winners Curis (CRIS) up 4.13%, Fibrocell Sciences (FCSC) up 3.42%, Geron (GERN) up 4.82%, Ignyta (RXDX) up 37.39%, and Ocera Therapeutics (OCRX) up 5.31%. Notable Rayno Dx and Tools Winners Cepheid (CPHD) up 6.45%, Illumina (ILMN) […]

Continue Reading 0

Biotech Rally Underway Trying to Overcome Gloomy Macro Data…Update-1

Update 11/16 PM Biotech Rally Underperforms Energy up 2.99% and Telecom up 1.81% The S&P and Dow rallied past Paris attack and terrorism concerns after an early morning stall. Biotechs underperformed weighed down by the Clovis Oncology (CLVS) NDA delay. The IBB was up 0.39% in a choppy session. Among the losers were mid-caps awaiting […]

Continue Reading 0

Biotech Bear Market: After the bubble burst…Update-1… 10/15 Rally

10/15 After the Close… XBI Up 7.26%…Green Screen…MOmentum is back Biotech stocks soared today in a broad rally showing a good appetite especially for small and mid-cap stocks. This could be a counter-trend rally in a biotech  bear market but there is a lot of money on the sidelines ready to be put to work. […]

Continue Reading 0

Biotech Stocks Crushed on Drug Pricing Issue: Caution…Update-1

Update-1… 9/22/15 …Biotech Stocks Trade Down Another Day  Biotech stocks were weak tracking NASDAQ which was down 1.5%. The IBB was down 1.49% to $335.40 flat over one month and up 10.57% YTD. The August low was $325 and the IBB is 16% off July 20 highs. The small cap weighted XBI was down 2.29% […]

Continue Reading 0

Biotech ETFs in A Bull Market: Positioning for a Q4 Rally… Part 2..Update

Update-1… 3P September 17 after FED Says No Rate Hike-Biotechs Rally NASDAQ up 0.8% after initial surge Apparently biotech stocks are sensitive to interest rate hikes as many analysts have suggested. Biotech companies need a continual inflow of capital and would be sensitive to higher interest rates. An analyst came on CNBC this AM suggesting […]

Continue Reading 0

Biotech ETFs Up YTD But 12% Losses in August Creates Downtrend…Update-2.. 9/4

Update -2… 9/8 Rally Time Today Forecasted by Friday’s Action ETF Summary -One month and YTD % FBT (12.36), +9.2% IBB (8.9), +11.3% XBI (10.12), +17.27% The five star Fidelity Select Biotech Portfolio (FBIOX) pretty much tracks the IBB up 11.66% YTD and down (8.52) for one month. Three relatively new top ten mid-cap holdings […]

Continue Reading 0

Biotech Breakdown: Seeking Relief Today

At Close: IBB down 2.35% to 342 at May bottom, XBI up 0.64% to 218 —- Two Hours to Go 2:15p EDT, NASDAQ Down 1.79% at 4792, IBB at $349 Biotech Breakdown: Relief Today Or Another Head Fake? Biotech stocks are trying to hold the May lows with the IBB at $342 but now at $349. […]

Continue Reading 0

Biotech Stocks Shake Off Fears of Greek Crisis…Update-1… 7/8

Update 7/8/15  12:10p EDT Strange Day with Computer Networks NYSE exchange is down and trading halted- all orders are cancelled. However stocks are trading on other exchanges but at very low volume. United Airlines Grounding Ends after two hour disruption due to a router issue. Apparently no connection but….some other WEB sites are down as well. e.g. […]

Continue Reading 0

Regulatory News for Rare Disease Products-Hot Stocks: BLUE,ICPT,SRPT …Updates

Update-2 uniQure up on deal with BMY (CURE) Cardiovascular Deal with Bristol Myers (BMY) The closing of the uniQure deal with Bristol Myers triggered a $50M payment. Three collaboration targets in cardiovascular and future areas. The stock is up 81% YTD but off its high of $35.50. Update-1 See Chart below of Emerging Orphan drug […]

Continue Reading 0

Rayno Life Science Stocks Move Higher: CLVS, RHHBY-ASCO Preview

Rayno Biopharmaceutical Stocks– ASCO Plays or Not Large Caps Rule Clovis Oncology (CLVS) up 16.7%, 79% YTD to $100 level! Several data CLVS Presentations for ASCO including two oral and six posters for non-small cell lung cancer and ovarian cancer. Also with a valuation of only $3.4B and three platform products in the pipeline including companion […]

Continue Reading 0

Biotech Buzz Is Broken…Update 4/30…#2

Gilead (GILD) Gilead Beats Q1 Estimates: $7.4B Sales HCV , EPS $2.94, stock up 2% after hours XBI Down Another 4% Down 12.84% in Five Days Weak Tape and Sell-Off Continues…4/30…NASDAQ at 4991 XBI down 1.6% now at 2/24 lows at 212 High fliers hit with profit taking…ADRO, AGIO, JUNO, KITE etc. Large cap Celgene […]

Continue Reading 0

Biotech Bull Market: Trends to Watch in 2015… #3

Biotech Sector Moves Up In Tiny Steps Risk Remains On AACR Next Week Will Move Cancer Stocks Biotech indices and ETFs are trying to hit new highs but momentum is easing and trading is choppy. Nonetheless we are moving up from the brief correction near channel lows at the end of Q1. Sentiment remains strong. […]

Continue Reading 0